MX2021008958A - Proteínas de unión a antígeno del receptor gamma anti-il2. - Google Patents

Proteínas de unión a antígeno del receptor gamma anti-il2.

Info

Publication number
MX2021008958A
MX2021008958A MX2021008958A MX2021008958A MX2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A MX 2021008958 A MX2021008958 A MX 2021008958A
Authority
MX
Mexico
Prior art keywords
receptor gamma
antibodies
binding proteins
antigen
fragments
Prior art date
Application number
MX2021008958A
Other languages
English (en)
Inventor
Jamie M Orengo
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021008958A publication Critical patent/MX2021008958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención proporciona anticuerpos y fragmentos de unión a antígeno (por ejemplo, anticuerpos humanos) que se unen específicamente al receptor gamma de IL2 humana (IL2R). También se proporcionan métodos para tratar o prevenir enfermedades mediadas por IL2R (por ejemplo, enfermedad de injerto contra huésped) usando los anticuerpos y fragmentos junto con métodos para fabricar los anticuerpos y fragmentos.
MX2021008958A 2019-02-01 2020-01-30 Proteínas de unión a antígeno del receptor gamma anti-il2. MX2021008958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799851P 2019-02-01 2019-02-01
PCT/US2020/015841 WO2020160242A1 (en) 2019-02-01 2020-01-30 Anti-il2 receptor gamma antigen-binding proteins

Publications (1)

Publication Number Publication Date
MX2021008958A true MX2021008958A (es) 2021-11-04

Family

ID=69740681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008958A MX2021008958A (es) 2019-02-01 2020-01-30 Proteínas de unión a antígeno del receptor gamma anti-il2.

Country Status (15)

Country Link
US (2) US11629195B2 (es)
EP (1) EP3917962A1 (es)
JP (1) JP2022519068A (es)
KR (1) KR20210123350A (es)
CN (1) CN113474370A (es)
AU (1) AU2020214812A1 (es)
BR (1) BR112021014074A2 (es)
CA (1) CA3126117A1 (es)
CL (1) CL2021002008A1 (es)
CO (1) CO2021009693A2 (es)
EA (1) EA202192090A1 (es)
IL (1) IL284579A (es)
MX (1) MX2021008958A (es)
SG (1) SG11202107272SA (es)
WO (1) WO2020160242A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022519068A (ja) * 2019-02-01 2022-03-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｉｌ２受容体ガンマ抗原結合タンパク質
CA3168737A1 (en) * 2020-04-21 2021-10-28 Jiaxi WU Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
WO2023078113A1 (en) * 2021-11-02 2023-05-11 Epimab Biotherapeutics (Hk) Limited Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
CN114990206B (zh) * 2022-06-02 2023-04-07 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Common γ-chain受体作为药物靶点在制备治疗狼疮性肾炎药物中的应用
WO2024015418A1 (en) 2022-07-13 2024-01-18 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
WO2024073606A1 (en) 2022-09-28 2024-04-04 Regeneron Pharmaceuticals, Inc. Antibody resistant modified receptors to enhance cell-based therapies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
WO1997017360A2 (en) 1995-11-09 1997-05-15 Dana-Farber Cancer Institute Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain
EP0918858A1 (en) 1996-05-10 1999-06-02 Biogen, Inc. Common gamma chain blocking agents
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
AU2001247899A1 (en) 2000-04-06 2001-10-23 Genetics Institute, Llc Polynucleotides encoding novel secreted proteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
AU2012205663B2 (en) 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
PT3366705T (pt) 2012-09-12 2023-07-19 Genzyme Corp Polipéptidos contendo fc com glicosilação alterada e função efetora reduzida
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
MX2017000821A (es) 2014-07-21 2017-08-18 Delinia Inc Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
ES2841799T3 (es) 2015-08-06 2021-07-09 Agency Science Tech & Res Anticuerpos frente a IL2R-Beta/cadena gamma común
WO2018156649A1 (en) 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
JP2022519068A (ja) * 2019-02-01 2022-03-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｉｌ２受容体ガンマ抗原結合タンパク質

Also Published As

Publication number Publication date
IL284579A (en) 2021-08-31
JP2022519068A (ja) 2022-03-18
US11629195B2 (en) 2023-04-18
US20200247894A1 (en) 2020-08-06
SG11202107272SA (en) 2021-07-29
CL2021002008A1 (es) 2022-02-04
CN113474370A (zh) 2021-10-01
BR112021014074A2 (pt) 2021-11-23
US20230279131A1 (en) 2023-09-07
CA3126117A1 (en) 2020-08-06
WO2020160242A1 (en) 2020-08-06
CO2021009693A2 (es) 2021-08-09
EP3917962A1 (en) 2021-12-08
EA202192090A1 (ru) 2021-10-20
AU2020214812A1 (en) 2021-09-23
KR20210123350A (ko) 2021-10-13

Similar Documents

Publication Publication Date Title
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA202091747A1 (ru) Составы антитела b7-h4
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2022002682A (es) Anticuerpos anti-cd73.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2021003119A (es) Anticuerpos anti-klrg1.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
PH12021551195A1 (en) Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
CR20220608A (es) Anticuerpos anti-cd200r1 y métodos de uso de estos
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.
MX2022010910A (es) Anticuerpos anti-gitr y usos de estos.